1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Synovial Sarcoma - Epidemiology Forecast – 2030

Synovial Sarcoma - Epidemiology Forecast – 2030

  • January 2021
  • 101 pages
  • ID: 6025293
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Synovial Sarcoma (SyS) – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of and historical and forecasted epidemiology of synovial sarcoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Synovial Sarcoma Disease Understanding
Synovial sarcoma (SyS), which may also be called malignant synovioma, is cancer that can originate from different types of soft tissue, such as muscle or ligaments. It is often found in the arm, leg, or foot and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen.
On a pathology report, SyS may be classified into different subtypes depending on what it looks like under the microscope or what specific gene mutation is involved. SyS is a high-grade tumor. It spreads to distant sites in up to 50% of cases. The symptoms caused by SyS depend on where the tumor forms. It is often first noticed as a painless lump. If it is near a nerve, it might cause pain or numbness as it grows.

Synovial Sarcoma Epidemiology
The SyS epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings
The total incident cases of synovial sarcoma patients are increasing in the 7MM during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted synovial sarcoma symptoms epidemiology segmented as the incidence of synovial sarcoma, gender-specific cases of synovial sarcoma, age-specific cases of synovial sarcoma, location-specific cases of synovial sarcoma, and stage-specific cases of synovial sarcoma. The report includes the incident scenario of synovial sarcoma symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Synovial Sarcoma Epidemiology
The epidemiology segment also provides the synovial sarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed incident cases of synovial sarcoma associated in 7MM countries were 1,610 in 2020.
• As per the estimates, the United States has the largest incident population of synovial sarcoma.
• Among the EU5 countries, Germany had the highest incident cases of synovial sarcoma, followed by France. On the other hand, Spain had the lowest prevalent cases with 116 cases in 2020.

Scope of the Report
• The synovial sarcoma report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The synovial sarcoma epidemiology report and model provide an overview of synovial sarcoma’s risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into synovial sarcoma’s historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of synovial sarcoma.
• The report provides the synovial sarcoma epidemiology segmentation by incident cases of Synovial Sarcoma in the 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by gender-specific prevalent cases of synovial sarcoma in 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by age-specific prevalent cases of synovial sarcoma in 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by location-specific cases of synovial sarcoma in 7MM.
• The report provides the synovial sarcoma epidemiology segmentation by stage-specific cases of synovial sarcoma in 7MM.

Report Highlights

• 10-year Forecast of Synovial Sarcoma epidemiology
• 7MM Coverage
• Incident Cases of Synovial Sarcoma
• Incident Cases according to segmentation: Gender-specific cases of Synovial Sarcoma
• Incident Cases according to segmentation: Age-specific cases of Synovial Sarcoma
• Incident Cases according to segmentation: Location-specific cases of Synovial Sarcoma
• Incident Cases according to segmentation: Stage-specific cases of Synovial Sarcoma

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population about synovial sarcoma?
• What are the key findings of the synovial sarcoma epidemiology across 7MM, and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of synovial sarcoma patients across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow by 7MM during the study period (2018–2030)?
• What are the disease risk, burdens, and unmet needs of synovial sarcoma?
• What are the currently available treatments for synovial sarcoma?

Reasons to buy
The synovial sarcoma epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global synovial sarcoma market.
• Quantify patient populations in the global synovial sarcoma market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for synovial sarcoma therapeutics in each of the markets covered.
• Understand the magnitude of the insomnia population by its total incident cases.
• Understand the magnitude of the synovial sarcoma population by its gender-specific cases.
• Understand the magnitude of the synovial sarcoma population by its age-specific cases.
• Understand the magnitude of the synovial sarcoma population by its location-specific cases.
• Understand the magnitude of the synovial sarcoma population by its stage-specific cases.
• The synovial sarcoma epidemiology report and model were written and developed by masters and Ph.D. level epidemiologists.
• The synovial sarcoma epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030
As reported in a recent report by Nedra et al. (2019) in the article titled “Incidence and prevalence of synovial sarcoma in the US: An analysis using SEER*Stat,” the age-adjusted incidence rate of synovial sarcoma was 0.177/100,000 in 2018. According to this report, there were about 580 cases of synovial sarcoma in 2018. The article also reports that SyS is more frequently manifested in patients aged 20–49 years, with the highest occurrence of new cases in patients between 45 and 49 years (incidence rate 0.26/100,000). They analyzed data from 18 registries of the Surveillance, Epidemiology, and End Results (SEER), and incidence rates were projected based on data from 2011 to 2015. These incidence projected by NCI and the above-mentioned article, along with other reports, were used to construct the forecasting model for the present report. The prevalence rate of SyS across all ages was 0.65/100,000 (estimated 2129 prevalent cases) as of January 1, 2018. The disease burden of SyS is generally extrapolated from overall soft tissue sarcoma (STS), with SyS accounting for 4.5% of all STS (587 cases estimated in 2018 in the US).
In another report titled “Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with a minimum follow-up of 10 years for survivors” written by Krieg et al. (2011), it was estimated that synovial sarcoma most frequently affects extremities in which it occurs most frequently in the lower (62%) and upper (21%) extremities. On a similar line, another article by Sultan et al. (2009) also noted that almost 70% of synovial sarcoma cases are located in extremities. Other sites that were affected most were the trunk, head, neck, lung, and pleura.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Uterine Cancer Therapeutics & Diagnostics Industry

  • $ 5450
  • April 2021
  • 388 pages

Abstract: - Global Uterine Cancer Therapeutics and Diagnostics Market to Reach $27.7 Billion by 2027 - Amid the COVID-19 crisis, the global market for Uterine Cancer Therapeutics and Diagnostics estimated ...

  • World
  • China
  • Cancer
  • Diagnostics
  • Industry analysis

Global Kaposi Sarcoma Industry $ 4950 April 2021


ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on